RxDoctor Payments Data

Sandra Baffoe-Bonnie, NP

Family · Lakeland, FLNPI 1285284216

Payments from drug & device makers

$2,378in general payments, 2019–2025

Across 71 payments — averaging $33.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$462
  • Boston Scientific$367
  • Alnylam Pharmaceuticals Inc.$301
  • Amgen$281
  • Boehringer Ingelheim$211
  • United Therapeutics Corporation$187
  • plus $569 from 9 others

What the payments were for

  • Food & beverage$2,378100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,378 in reported general payments places this provider in the 80th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$26,803
Medicare patients
218
Services billed
343

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban43$37,064
Repatha SureclickEvolocumab18$18,016
EntrestoSacubitril/Valsartan11$16,985
BrilintaTicagrelor32$16,550
Dabigatran EtexilateDabigatran Etexilate Mesylate13$1,384
ClopidogrelClopidogrel Bisulfate77$777
Carvedilol54$654
Sucralfate21$627
Rosuvastatin Calcium18$621
Metoprolol Succinate39$490
Amiodarone Hcl20$484
Diltiazem 24hr Er (Cd)Diltiazem Hcl17$447
Nitroglycerin17$321
Digoxin15$308
Atorvastatin Calcium23$217

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$128$37,06443 claims
AstraZenecaBrilinta$125$16,55032 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 14,618 family providers in Florida.

Other family in Lakeland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →